Published in
UROLOGICONCOLOGY
2022
September 2022, Volume 40, Issue 9, Pages 408.e9-408.e18; doi: 10.1016/j.urolonc.2022.06.002
Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study Eric A. Klein, Alan Partin, Yair Lotan, Jack Baniel, Martin Dineen, Jason Hafron, Kannan Manickam, Marc Pliskin, Matthew Wagner, Aimee Kestranek, Mark Stovsky
Objective Methodology
To validate the diagnostic performance of IsoPSA for clinically significant prostate cancer (csPCa) risk on biopsy in men age ≥ 50 with total PSA ≥ 4 ng/mL. 5-year prospective, multicenter study of 888 men scheduled for prostate biopsy at eight academic and community medical centers. Estimate the overall performance characteristics of IsoPSA to identify the risk of csPCa; Compare the diagnostic accuracy of IsoPSA to total PSA and % free PSA; evaluate subgroups (total PSA 4-10 ng/mL, total PSA >10 ng/mL, biopsy naïve, prior negative biopsy).
Results
IsoPSA outperformed total PSA and % free PSA on area under the ROC curve, specificity, and positive and negative predictive values at similar sensitivity. Using the IsoPSA Index cutoff for csPCa (>6), an estimated 46% of biopsies could be avoided in low-risk patients. IsoPSA Index (>6)
Total PSA (>4 ng/mL)
% Free PSA (≤25%)
Sensitivity*
90.2%
93.1%
94.7%
Specificity
45.5%
20.2%
13.7%
PPV
47.7%
36.1%
38.2%
NPV
89.3%
85.8%
82.0%
AUC
0.783
0.672
0.724
n (population): IsoPSA Index = 888 | Total PSA = 1112 | % Free PSA = 938 Prevalence for csPCa: IsoPSA Index = 0.356 | Total PSA = 0.326 | % Free PSA = 0.360 *Differences in sensitivity are not statistically significant
Conclusion
IsoPSA diagnostic performance and predictive value is validated for csPCa in men age ≥50 with total PSA ≥4 ng/mL undergoing diagnostic biopsy. IsoPSA outperforms total and % free PSA in discriminating the risk of prostate cancer on biopsy.
REDUCE OVER-DETECTION AND OVER-TREATMENT OF PCa • IsoPSA outperformed total PSA and % free PSA on specificity at similar sensitivity • An estimated 46% of biopsies could have been avoided compared to 20% for total PSA and 14% for % free PSA
CONSISTENT PERFORMANCE FOR BIOPSY NAÏVE & REPEAT BIOPSY • IsoPSA may have utility in managing patients with persistently elevated and increasing PSA levels over time
IsoPSA MAINTAINS ACCURACY ACROSS A BROAD RANGE OF PSA (4-100 ng/mL) • In a clinical study, ~25% of patients had total PSA levels of 10 ng/mL or greater. For this group: – IsoPSA demonstrated 92% sensitivity – 48% of patients were negative for csPCa on biopsy
ADDITIONAL PUBLISHED DATA ON IsoPSA IsoPSA ADDS CLARITY TO MRI1 • Negative (PI-RADS 1-2) Help assess the presence or absence of MRI-invisible csPCa • Equivocal (PI-RADS 3) Gain additional insight to triage patients
UNAFFECTED BY THE USE OF BPH MEDICATIONS2 • IsoPSA test results are unaffected by commonly used medications (5-ARIs and α-blockers) for symptoms of benign prostatic hyperplasia
1. Benidir T, et al. Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA. Urology. 2023 Jun;176:115-120. 2. Scovell JM, et al. IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study. Urology. 2023 May;175:132-136.
View this and other IsoPSA publications
Learn more about IsoPSA at IsoPSA.com 3615 Superior Ave. Suite 4407C ©2023 Cleveland Diagnostics, IsoPSA and all associated logos are trademarks of Cleveland Diagnostics, Inc. MKTG-VSA004
Cleveland, OH 44114